Evogene Ltd. has announced its financial results for the second quarter and first half of 2025. The company reported total revenues of approximately $3.2 million for the first half of 2025, up from $2.3 million during the same period in 2024. This increase was mainly attributed to higher seed sales by Casterra. Sales and marketing expenses for the first half of 2025 decreased to approximately $0.8 million from $1.1 million in the first half of 2024, primarily due to reductions in personnel costs across Evogene, AgPlenus, and Biomica. In the second quarter of 2025, sales and marketing expenses were approximately $0.4 million, a decrease from approximately $0.6 million in the second quarter of 2024. The company held consolidated cash, cash equivalents, and short-term bank deposits of approximately $11.7 million as of June 30, 2025. During the second quarter of 2025, Evogene's consolidated cash usage was approximately $2.4 million. Excluding Lavie Bio and Biomica, the cash usage was approximately $1.0 million. Evogene's total operating expenses, net, for the first half of 2025 were approximately $7.7 million, down from approximately $11.1 million in the first half of 2024. This reduction is largely due to a decrease in the activity of Evogene's subsidiaries. The company's cash position does not yet reflect proceeds from the sale of Lavie Bio's assets and the MicroBoost AI for Ag technology, a transaction completed in July 2025. The company is at a significant inflection point as it focuses on redefining small molecule innovation for human health and sustainable agriculture.